Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Connect Biopharma Holdings (CNTB) Research & Development (2024 - 2025)

Connect Biopharma Holdings' Research & Development history spans 2 years, with the latest figure at $11.1 million for Q3 2025.

  • For Q3 2025, Research & Development rose 23.32% year-over-year to $11.1 million; the TTM value through Sep 2025 reached $32.8 million, changed N/A, while the annual FY2024 figure was $29.3 million, 44.8% down from the prior year.
  • Research & Development for Q3 2025 was $11.1 million at Connect Biopharma Holdings, up from $8.8 million in the prior quarter.
  • Across five years, Research & Development topped out at $11.1 million in Q3 2025 and bottomed at $5.3 million in Q2 2024.